Latest

OpenAI officially announced this Monday that it has started testing advertising features for select ChatGPT users in the United States, marking a decisive step toward commercial monetization. Although OpenAI emphasized that this move aims to cover costly infrastructure expenses through ad revenue in order to maintain its free service operations,

``` Deutsche Bank points out that amid the current global fixed income markets, a giant "elephant" is lurking in the Japanese government bond (JGB) market: the flattening trade of the yield curve between the 2-year and 30-year JGBs (JGB 2s30s). According to the Wind Chaser Trading Desk, on February

``` Amazon is planning to establish a brand-new content marketplace to connect publishers with AI developers, providing infrastructure for monetizing digital content in the AI era. According to sources cited by The Information, Amazon has discussed this project with publishing industry executives. The core logic of the platform is to create

``` Author | Zhou Zhiyu On the eve of the Spring Festival in 2026, the tension in China’s internet sphere was fiercer than ever before. On February 10th, Wallstreetcn learned from Baidu insiders that Baidu had recently quietly launched a project codenamed the “O Plan.” Unlike previous interdepartmental collaborations, this time

Author | Huang Yu The long-standing “intelligence wall” in the field of embodied intelligence is being broken down bit by bit. On February 10, Alibaba DAMO Academy officially released the embodied intelligence brain foundation model RynnBrain, and open-sourced a full series of 7 models at once, including the industry's

Alphabet is launching an unprecedented financing offensive in global markets. After completing a record-breaking $20 billion USD bond issuance, Google’s parent company swiftly turned to the European market, debuting its first Swiss franc-denominated bonds and offering a rare century-long British pound bond to meet its massive $185 billion AI

On February 10, AstraZeneca projected that its adjusted earnings per share will achieve double-digit percentage growth in 2026, in line with market expectations. The company stated that the strong sales momentum of its oncology drug business will effectively offset the impact of patent expirations in its core diabetes drug portfolio,